Monitoring ICS underuse in asthma and over-reliance on SABA: A sponsored supplement
Improving outcomes in asthma as an inflammatory disease: spotlight on monitoring ICS underuse and over-reliance on SABA: A sponsored supplement
A report of a multi-disciplinary consensus meeting held in December 2018. AstraZeneca organised and fully funded the meeting and the production of this supplement. All meeting participants reviewed and commented upon the content of this supplement. The views expressed are not necessarily those of AstraZeneca or PCRS.
Date of preparation: April 2019